Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BAY1862864 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1a | EXPERIMENTAL | Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 1.5 MBq (2 mg antibody chelator conjugate \[ACC\]). |
| Cohort 1b | EXPERIMENTAL | Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 1.5 MBq (10 mg ACC). |
| Cohort 2 | EXPERIMENTAL | Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 3.1 MBq (10 mg ACC). |
| Cohort 3 | EXPERIMENTAL | Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 4.6 MBq (10 mg ACC). |
| Cohort 4 | EXPERIMENTAL | Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 6.1 MBq (10 mg ACC). |
| Name | Type | Description |
|---|---|---|
| BAY1862864 | DRUG | Radiopharmaceutical, injection: Up to four treatment cycles lasting six weeks each; in each cycle, a single treatment on Day 1. In this dose-escalation part of the study, the radioactivity dose will start at 1.5 MBq and increase in steps of 1.5 MBq, with a antibody-chelator conjugate dose of 2 or 10 mg. |
Inclusion Criteria: * Subject has relapsed or refractory CD22-positive histologically confirmed NHL * An archival paraffin-embedded tissue or fresh biopsy is available for the retrospective quantitative assessment of CD22 levels * Bone marrow involvement of cellular marrow with lymphoma determined ...
BAY1862864 is an investigational small molecule being studied for the treatment of relapsed or refractory CD22-positive Non-Hodgkin's lymphoma. It is administered as an injection and is currently in Phase 1 clinical development. The drug is not approved and remains under investigation for this oncology indication.
BAY1862864 is being developed by Bayer AG, a multinational pharmaceutical company. Bayer's stock is traded over-the-counter under the ticker symbol BAYRY. The company is conducting clinical research to evaluate the safety and tolerability of this investigational drug in patients with Non-Hodgkin's lymphoma.
BAY1862864 is in Phase 1 clinical development. A Phase 1 trial has been completed to assess its safety and tolerability in patients with relapsed or refractory CD22-positive Non-Hodgkin's lymphoma. The drug is investigational and has not received regulatory approval for any use.
BAY1862864 has been studied in one completed Phase 1 clinical trial, identified as NCT02581878. This trial evaluated the safety and tolerability of BAY1862864 injection in 21 subjects with relapsed or refractory CD22-positive Non-Hodgkin's lymphoma. The study was conducted in Sweden and the United Kingdom.
No alternative names for BAY1862864 have been reported. The drug is identified solely by its code name BAY1862864 in clinical trial records. It is an investigational small molecule being developed by Bayer AG for the treatment of Non-Hodgkin's lymphoma.